• Contact us: 01476 247 007
    PDSlogo1PDSlogo1PDSlogo1PDSlogo1
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Our Partners
      • External Team
    • News
    • Get in touch
    ✕
    • Filter by
    • Categories
    • Tags
    • Authors
    • Show all
    • All
    • Brexit Updates
    • Industry News
    • NCPP
    • Patient Information
    • Pharmacovigilance
    • Risk Management
    • All
    • Aimovig
    • Brexit updates
    • British Association for the Study of Headache
    • CGRP
    • chronic migraine
    • Deputy QPPV for Pharmacovigilance
    • EMA latest guidance
    • erenumab
    • EU MA
    • EU QPPV
    • EU QPPV for Pharmacovigilance
    • EU/EEA QPPV
    • European Marketing Authorisation Holders (MAH)
    • GCP inspections
    • Good Clinical Practice inspections
    • MAH Service
    • Marketing Authorisation Holders
    • MHRA latest guidance
    • MHRA post-transition period information
    • National Contact Person for Pharmacovigilance (NCPP)
    • NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    • Novartis
    • Periodic Safety Update Reports
    • pharmacovigilance
    • Pharmacovigilance (QPPV)
    • Pharmacovigilance (QPPV) provision post-Brexit
    • Post-Authorisation Safety Studies-protocols and final study reports
    • PSMF (pharmacovigilance system master file)
    • Pure Drug Safety
    • QPPV (Qualified Person for Pharmacovigilance)
    • QPPVs based in the UK
    • remain compliant in the UK
    • Responsible Person for Eudravigilance in clinical trials
    • Risk Management Plans
    • severe migraine
    • the transition period for Pharmacovigilance and Regulatory
    • UK and non-UK Individual Case Safety Reports
    • UK QPPV
    • All
    • bone
    • Liselle Barnsley
    23rd October 2020
    MHRA post-transition period information from Pure Drug Safety
    23rd October 2020

    MHRA and EMA latest guidance on Brexit

    As at 23 October 2020, the situation regarding a Deal or No Deal Brexit is extremely fluid. As such, rather than bombard you with our guesses […]
    Do you like it?
    Read more

    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    © 2019 - 2024 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Built + Hosted by GIGER MEDIA | Designed by Gather Creative | Content managed by Tailored Marketing Solutions